Anzeige
Mehr »
Mittwoch, 30.07.2025 - Börsentäglich über 12.000 News
Geheime Millionen-Käufe in Bitcoin & Altcoins - ohne Wallet, ohne Risiko? Jetzt wird's spannend
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A40EWG | ISIN: US79400X4043 | Ticker-Symbol: FP10
NASDAQ
30.07.25 | 19:24
0,772 US-Dollar
-21,95 % -0,217
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
SALARIUS PHARMACEUTICALS INC Chart 1 Jahr
5-Tage-Chart
SALARIUS PHARMACEUTICALS INC 5-Tage-Chart

Aktuelle News zur SALARIUS PHARMACEUTICALS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DiSalarius Pharmaceuticals stock soars after Nasdaq extends compliance deadline5
DiPre-market Movers: DURECT Corporation, Salarius Pharmaceuticals, ScanTech AI Systems, AIM ImmunoTech, Bakkt Holdings339OTTAWA (dpa-AFX) - The following are some of the stocks making big moves in Tuesday's pre-market trading (as of 07.25 A.M. ET).In the Green DURECT Corporation (DRRX) is up over 267% at $2.03. Salarius...
► Artikel lesen
MoSalarius Pharmaceuticals erhält von der NASDAQ Aufschub zur Erfüllung der Listing-Anforderungen3
MoSalarius Pharmaceuticals, Inc. - 8-K, Current Report1
21.07.Salarius Pharmaceuticals, Inc. - 8-K, Current Report2
SALARIUS PHARMACEUTICALS Aktie jetzt für 0€ handeln
14.07.Salarius Pharmaceuticals granted additional extension to regain Nasdaq compliance1
14.07.Salarius Pharmaceuticals, Inc.: Salarius Pharmaceuticals Granted Additional Extension to Regain Compliance with Nasdaq's Stockholders' Equity Standard89HOUSTON, July 14, 2025 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX) (Salarius or the Company) announces that on July 10, 2025 the Company received notification from The Nasdaq...
► Artikel lesen
09.07.Salarius Pharmaceuticals, Inc.: Salarius Pharmaceuticals' Seclidemstat Demonstrates Supporting Role in Inhibiting Validated Oncology Target LSD1 in Two Recently Published Studies1
08.07.Aktionäre von Salarius Pharmaceuticals genehmigen Reverse-Aktiensplit und Aktienausgabe1
08.07.Salarius Pharmaceuticals, Inc. - 8-K, Current Report1
16.06.Salarius Pharmaceuticals, Inc. - S-1/A, General form for registration of securities4
11.06.Salarius Pharmaceuticals, Inc. - 8-K, Current Report1
14.05.Salarius Pharmaceuticals, Inc. - 10-Q, Quarterly Report1
25.04.Salarius Pharmaceuticals, Inc. - 8-K, Current Report1
16.04.Salarius Pharmaceuticals, Inc.: Salarius Pharmaceuticals Merger Partner, Decoy Therapeutics, Appoints Renowned MIT Professor Robert S. Langer to its Scientific Advisory Board13
28.03.Salarius Pharmaceuticals, Inc. - 8-K, Current Report1
26.03.Salarius Pharmaceuticals, Inc.: Salarius Pharmaceuticals Merger Partner, Decoy Therapeutics, Announces its Novel Inhibitors Show Promising In Silico Activity Against Measles and Related Viruses221CAMBRIDGE, Mass. and HOUSTON, March 26, 2025 (GLOBE NEWSWIRE) -- Decoy Therapeutics Inc. (Decoy), a privately held preclinical biopharmaceutical company engineering the next generation of peptide-conjugate...
► Artikel lesen
24.03.Salarius Pharmaceuticals GAAP EPS of -$5.791
24.03.Salarius Pharmaceuticals, Inc.: Salarius Pharmaceuticals Reports 2024 Financial Results and Provides Business Update574Contemplated merger with Decoy Therapeutics progressing as planned; upon closing, combined company expected to accelerate clinical development of novel peptide conjugate therapeutics for treating...
► Artikel lesen
21.03.Salarius Pharmaceuticals, Inc. - 10-K, Annual Report2
Weiter >>
23 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1